{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:25:42Z","timestamp":1794302742813,"version":"4.9.0"},"reference-count":370,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.eprac.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:00:20Z","timestamp":1773748820000},"page":"473-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes \u2013 2026 Update"],"prefix":"10.1016","volume":"32","author":[{"given":"Susan L.","family":"Samson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyathama","family":"Vellanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Blonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh D.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Izuora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia C.","family":"Low Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheow Peng","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Iris","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifka","family":"Schulman-Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Twining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy Marcos","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4158\/EP.13.3.260","article-title":"Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE\/AACE Diabetes Road Map Task Force","volume":"13","author":"Jellinger","year":"2007","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/endp.19.2.a38267720403k242","article-title":"AACE comprehensive diabetes management algorithm 2013","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4158\/EP151063.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm--2015 executive summary","volume":"21","author":"Garber","year":"2015","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP151126.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary","volume":"22","author":"Garber","year":"2016","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4158\/CS-2018-0535","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary","volume":"25","author":"Garber","year":"2019","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease - 2025 update","volume":"31","author":"Nadolsky","year":"2025","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.eprac.2025.07.014","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for management of adults with dyslipidemia - 2025 update","volume":"31","author":"Patel","year":"2025","journal-title":"Endocrine Pract"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocr Pract"},{"issue":"10402","key":"10.1016\/j.eprac.2026.01.006_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.eprac.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2026.01.006_bib16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.eprac.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.108101","article-title":"DCRM multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"36","author":"Handelsman","year":"2022","journal-title":"J Diabetes Complications"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S2213-8587(24)00126-8","article-title":"Diabetes distress: the psychological burden of living with diabetes","volume":"12","author":"Poole","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eprac.2023.03.272","volume":"29","author":"Nadolsky","year":"2023","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4158\/EP161688.PS","article-title":"Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement","volume":"23","author":"Mechanick","year":"2017","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib28","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1210\/clinem\/dgab848","article-title":"New horizons. A new paradigm for treating to target with second-generation obesity medications","volume":"107","author":"Garvey","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jclinpath-2017-204755","article-title":"HbA1c: a review of non-glycaemic variables","volume":"72","author":"Campbell","year":"2019","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/dc18-1131","article-title":"Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes","volume":"41","author":"Lu","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib32","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib33","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/dia.2017.0388","article-title":"Beyond HbA1c: comparing glycemic variability and glycemic indices in predicting hypoglycemia in type 1 and type 2 diabetes","volume":"20","author":"Rama Chandran","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"1 Suppl 1","key":"10.1016\/j.eprac.2026.01.006_bib35","first-page":"S128","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib36","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/dc16-1769","article-title":"Toward defining the threshold between low and high glucose variability in diabetes","volume":"40","author":"Monnier","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diabres.2014.02.003","article-title":"Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects","volume":"104","author":"Jin","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/jdi.13453","article-title":"Defining the target value of the coefficient of variation by continuous glucose monitoring in Chinese people with diabetes","volume":"12","author":"Mo","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/1932296818758105","article-title":"Different indexes of glycemic variability as identifiers of patients with risk of hypoglycemia in type 2 diabetes mellitus","volume":"12","author":"G\u00f3mez","year":"2018","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1c to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eprac.2021.04.008","article-title":"American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus","volume":"27","author":"Grunberger","year":"2021","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib43","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc18-1581","article-title":"Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring","volume":"41","author":"Bergenstal","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/dia.2020.0501","article-title":"HbA1c and glucose management indicator discordance: a real-world analysis","volume":"23","author":"Perlman","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"9739","key":"10.1016\/j.eprac.2026.01.006_bib45","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.eprac.2026.01.006_bib46","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.eprac.2026.01.006_bib47","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/0003-4819-141-6-200409210-00006","article-title":"Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk","volume":"141","author":"Khaw","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2026.01.006_bib49","article-title":"Benefits and harms of intensive glycemic control in patients with type 2 diabetes","volume":"367","author":"Rodriguez-Gutierrez","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib51","doi-asserted-by":"crossref","first-page":"554","DOI":"10.7326\/0003-4819-154-8-201104190-00007","article-title":"Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials","volume":"154","author":"Ismail-Beigi","year":"2011","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.006_bib52","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/dom.14455","article-title":"Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis","volume":"23","author":"Powell","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dom.13088","article-title":"Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"10.1016\/j.eprac.2026.01.006_bib54","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMe0807625","article-title":"UKPDS and the legacy effect","volume":"359","author":"Chalmers","year":"2008","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2026.01.006_bib55","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib56","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc17-1144","article-title":"The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study)","volume":"42","author":"Laiteerapong","year":"2019","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.eprac.2026.01.006_bib57","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2021.7444","article-title":"Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial","volume":"325","author":"Martens","year":"2021","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.eprac.2026.01.006_bib58","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/jama.2021.6530","article-title":"Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes","volume":"325","author":"Karter","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","article-title":"Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial","volume":"8","author":"Haak","year":"2017","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib60","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00125-024-06107-6","article-title":"Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"67","author":"Jancev","year":"2024","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib61","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1932296818790994","article-title":"Behavior modification in prediabetes and diabetes: potential use of real-time continuous glucose monitoring","volume":"13","author":"Ehrhardt","year":"2019","journal-title":"J Diabetes Sci Technol"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib62","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1089\/dia.2023.0612","article-title":"The potential impact of continuous glucose monitoring use on diabetes-related attitudes and behaviors in adults with type 2 diabetes: a qualitative investigation of the patient experience","volume":"26","author":"Clark","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diabres.2008.06.015","article-title":"Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes","volume":"82","author":"Yoo","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib64","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/cd24-0106","article-title":"Continuous glucose monitoring (CGM) as a behavior modification tool: a case series on CGM-guided nutrition in people with type 2 diabetes not using insulin","volume":"43","author":"Ettestad","year":"2025","journal-title":"Clin Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.diabres.2008.01.006","article-title":"Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: a randomized clinical trial","volume":"80","author":"Allen","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib66","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.2337\/dc15-2836","article-title":"Continuous glucose monitoring in the self-management of type 2 diabetes: a paradigm shift","volume":"39","author":"Cox","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/dia.2015.0285","article-title":"Self-monitoring using continuous glucose monitors with real-time feedback improves exercise adherence in individuals with impaired blood glucose: a pilot study","volume":"18","author":"Bailey","year":"2016","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib68","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1089\/dia.2011.0088","article-title":"A continuous glucose monitoring and problem-solving intervention to change physical activity behavior in women with type 2 diabetes: a pilot study","volume":"13","author":"Allen","year":"2011","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib69","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jdiacomp.2017.02.012","article-title":"Updated risk factors should be used to predict development of diabetes","volume":"31","author":"Bethel","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"25","key":"10.1016\/j.eprac.2026.01.006_bib70","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.eprac.2026.01.006_bib71","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1001\/jama.285.16.2109","article-title":"Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study","volume":"285","author":"de Vegt","year":"2001","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.eprac.2026.01.006_bib72","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib73","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/aje\/kwf145","article-title":"Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study","volume":"156","author":"Laaksonen","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.eprac.2026.01.006_bib74","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib76","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2337\/diabetes.54.1.158","article-title":"Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study","volume":"54","author":"Laaksonen","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib77","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.20.4.537","article-title":"Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study","volume":"20","author":"Pan","year":"1997","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-1725","article-title":"Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial","volume":"160","author":"Salas-Salvad\u00f3","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2026.01.006_bib79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dc10-1288","article-title":"Erratum. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial","volume":"34","author":"Salas-Salvad\u00f3","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archinte.159.3.285","article-title":"Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial","volume":"159","author":"Svetkey","year":"1999","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib82","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.2337\/dc10-1548","article-title":"Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary","volume":"33","author":"Colberg","year":"2010","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib83","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.2337\/dc10-9990","article-title":"Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement","volume":"33","author":"Colberg","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3143","article-title":"Two-year-supervised resistance training prevented diabetes incidence in people with prediabetes: a randomised control trial","volume":"35","author":"Dai","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.eprac.2026.01.006_bib85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1479-5868-11-2","article-title":"Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta-analysis","volume":"11","author":"Aguiar","year":"2014","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"25 Pt B","key":"10.1016\/j.eprac.2026.01.006_bib86","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.jacc.2013.11.003","article-title":"2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Eckel","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib87","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib88","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.eprac.2026.01.006_bib89","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.eprac.2026.01.006_bib90","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10077","key":"10.1016\/j.eprac.2026.01.006_bib91","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib92","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.eprac.2026.01.006_bib93","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib95","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1381\/0960892055002202","article-title":"BioEnterics intragastric balloon: the Italian experience with 2,515 patients","volume":"15","author":"Genco","year":"2005","journal-title":"Obes Surg"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib96","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.soard.2014.12.006","article-title":"The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity","volume":"11","author":"Ponce","year":"2015","journal-title":"Surg Obes Relat Dis"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib97","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.soard.2014.03.005","article-title":"Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study","volume":"10","author":"Marinos","year":"2014","journal-title":"Surg Obes Relat Dis"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib98","first-page":"1346","volume":"25","author":"Mechanick","year":"2019","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib99","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg Obes Relat Dis"},{"issue":"9323","key":"10.1016\/j.eprac.2026.01.006_bib100","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib101","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib102","first-page":"1276","article-title":"Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes","volume":"47","author":"Phillip","year":"2024","journal-title":"Diabetes Care"},{"issue":"3-4","key":"10.1016\/j.eprac.2026.01.006_bib103","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00508-018-1434-9","article-title":"Overweight and obesity in type 1 diabetes equal those of the general population","volume":"131","author":"Fellinger","year":"2019","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib104","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/EJE-14-0911","article-title":"Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis","volume":"173","author":"Donga","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib105","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00125-019-4863-8","article-title":"Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes","volume":"62","author":"Thomas","year":"2019","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib106","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2337\/cd18-0088","article-title":"Misdiagnosis and diabetic ketoacidosis at diagnosis of type 1 diabetes: patient and caregiver perspectives","volume":"37","author":"Mu\u00f1oz","year":"2019","journal-title":"Clin Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2026.01.006_bib107","first-page":"S27","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib108","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/dc14-2391","article-title":"BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening","volume":"38","author":"Hsu","year":"2015","journal-title":"Diabetes Care"},{"issue":"9328","key":"10.1016\/j.eprac.2026.01.006_bib109","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(02)09512-0","article-title":"WHO reassesses appropriate body-mass index for Asian populations","volume":"360","author":"Choo","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib110","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1253\/circj.CJ-16-1087","article-title":"Obesity and overweight in Asian people","volume":"80","author":"Goda","year":"2016","journal-title":"Circ J"},{"issue":"Suppl 3","key":"10.1016\/j.eprac.2026.01.006_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib112","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc19-0532","article-title":"Racial\/ethnic disparities in the prevalence of diabetes and prediabetes by BMI: patient outcomes research to advance learning (PORTAL) multisite cohort of adults in the U.S","volume":"42","author":"Zhu","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib113","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.metabol.2015.03.009","article-title":"Characterization of metabolically unhealthy normal-weight individuals: risk factors and their associations with type 2 diabetes","volume":"64","author":"Eckel","year":"2015","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib114","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc21-0770","article-title":"Adult-onset type 1 diabetes: current understanding and challenges","volume":"44","author":"Leslie","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib115","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.7326\/M23-1707","article-title":"Age at diagnosis in U.S. adults with type 1 diabetes","volume":"176","author":"Fang","year":"2023","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib116","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib117","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2337\/dbi20-0017","article-title":"Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel","volume":"69","author":"Buzzetti","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.eprac.2026.01.006_bib118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/5584_2020_533","article-title":"Latent autoimmune diabetes in adults: a review of clinically relevant issues","volume":"1307","author":"Hern\u00e1ndez","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.eprac.2026.01.006_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.959011","article-title":"Latent autoimmune diabetes in adults: a focus on \u03b2-cell protection and therapy","volume":"13","author":"Yin","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib120","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1210\/clinem\/dgaf194","article-title":"Establishing screening programs for presymptomatic type 1 diabetes: practical guidance for diabetes care providers","volume":"110","author":"Leichter","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib121","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/0003-4819-144-5-200603070-00011","article-title":"Narrative review: ketosis-prone type 2 diabetes mellitus","volume":"144","author":"Umpierrez","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib122","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17446651.2019.1561270","article-title":"Evaluation and management of ketosis-prone diabetes","volume":"14","author":"Gaba","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.01.006_bib123","first-page":"145","article-title":"Syndromes of ketosis-prone diabetes","volume":"130","author":"Balasubramanyam","year":"2019","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"14","key":"10.1016\/j.eprac.2026.01.006_bib124","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1056\/NEJM198904063201401","article-title":"A comparison of childhood and adult type I diabetes mellitus","volume":"320","author":"Karjalainen","year":"1989","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib125","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dme.12159","article-title":"The clinical utility of C-peptide measurement in the care of patients with diabetes","volume":"30","author":"Jones","year":"2013","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib126","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.tem.2021.02.001","article-title":"Autoantibody-negative type 1 diabetes: a neglected subtype","volume":"32","author":"Patel","year":"2021","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib127","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eprac.2023.01.004","article-title":"The predictive ability of C-peptide in distinguishing type 1 diabetes from type 2 diabetes: a systematic review and meta-analysis","volume":"29","author":"Iqbal","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.01.006_bib128","doi-asserted-by":"crossref","unstructured":"Schleicher E, Kabytaev K, Nauck M, et al. Call for standardization of C-peptide measurement. J Diabetes Sci Technol. Posted online Aug 8. Accessed \u2022\u2022\u2022. https:\/\/doi.org\/10.1177\/19322968251362848","DOI":"10.1177\/19322968251362848"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib129","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/dc07-2451","article-title":"Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes","volume":"31","author":"Greenbaum","year":"2008","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib130","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"64","author":"Holt","year":"2021","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib131","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib132","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2265.2011.04055.x","article-title":"Metabolic and cardiovascular outcomes in patients with Cushing\u2019s syndrome of different aetiologies during active disease and 1 year after remission","volume":"75","author":"Giordano","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib133","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11102-024-01438-4","article-title":"Is diabetes with acromegaly for life?","volume":"27","author":"Samson","year":"2024","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib134","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11102-024-01415-x","article-title":"Glucose metabolism outcomes after pituitary surgery in patients with acromegaly","volume":"27","author":"Pascual-Corrales","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11102-024-01477-x","article-title":"Treatment of acromegaly-induced diabetes: an updated proposal","volume":"28","author":"Biagetti","year":"2024","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.006_bib136","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41574-024-00993-x","article-title":"Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management","volume":"20","author":"Esposito","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib137","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2006-0997","article-title":"Cushing\u2019s syndrome: important issues in diagnosis and management","volume":"91","author":"Findling","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib138","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.2337\/dc24-2841","article-title":"Prevalence of hypercortisolism in difficult-to-control type 2 diabetes","volume":"48","author":"Buse","year":"2025","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib139","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc25-1055","article-title":"Inadequately controlled type 2 diabetes and hypercortisolism: improved glycemia with mifepristone treatment","volume":"48","author":"DeFronzo","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.01.006_bib140","series-title":"Diabetes Management in Hospitalized Patients","first-page":"207","article-title":"Type 3c diabetes","author":"Charitou","year":"2023"},{"key":"10.1016\/j.eprac.2026.01.006_bib141","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fendo.2018.00020","article-title":"Cystic fibrosis-related diabetes","volume":"9","author":"Kayani","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2026.01.006_bib142","series-title":"Diabetes Management in Hospitalized Patients","first-page":"217","article-title":"Cystic fibrosis-related diabetes","author":"Richstein","year":"2023"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib143","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1093\/ejendo\/lvaf172","article-title":"Maturity onset diabetes of the young and beyond: the changing face of single-gene diabetes","volume":"193","author":"Laver","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib144","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s13300-020-00864-4","article-title":"Treatment options for MODY patients: a systematic review of literature","volume":"11","author":"Delvecchio","year":"2020","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mayocp.2021.11.007","article-title":"Diagnosis and treatment of acromegaly: an update","volume":"97","author":"Ershadinia","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib147","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00125-011-2418-8","article-title":"The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes","volume":"55","author":"Shields","year":"2012","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib148","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.eprac.2022.07.014","article-title":"Glucocorticoid-induced hyperglycemia including dexamethasone-associated hyperglycemia in COVID-19 infection: a systematic review","volume":"28","author":"Brooks","year":"2022","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib149","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/db19-0828","article-title":"Tacrolimus-induced BMP\/SMAD signaling associates with metabolic stress-activated FOXO1 to trigger \u03b2-cell failure","volume":"69","author":"Tri\u00f1anes","year":"2020","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-017-0203-0","article-title":"Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure","volume":"15","author":"Lombardi","year":"2017","journal-title":"Cell Commun Signal"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib151","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/dom.15575","article-title":"An update review of post-transplant diabetes mellitus: concept, risk factors, clinical implications and management","volume":"26","author":"Kanbay","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143405","article-title":"Tacrolimus induces insulin resistance and increases the glucose absorption in the jejunum: a potential mechanism of the diabetogenic effects","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib153","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","article-title":"American Association of Clinical Endocrinology disease state clinical review: evaluation and management of immune checkpoint inhibitor-mediated endocrinopathies: a practical case-based clinical approach","volume":"28","author":"Yuen","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib154","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/clinem\/dgad685","article-title":"Checkpoint inhibitor-associated autoimmune diabetes mellitus is characterized by C-peptide loss and pancreatic atrophy","volume":"109","author":"Wu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2026.01.006_bib155","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.2337\/diabetes.53.2007.S103","article-title":"Mitochondrial diabetes: molecular mechanisms and clinical presentation","volume":"53","author":"Maassen","year":"2004","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.006_bib156","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11892-022-01485-w","article-title":"Lipodystrophy for the diabetologist-what to look for","volume":"22","author":"Patni","year":"2022","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.eprac.2026.01.006_bib157","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1475-2840-10-39","article-title":"Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study","volume":"10","author":"Flores-Le Roux","year":"2011","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib158","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ahj.2013.01.005","article-title":"Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome","volume":"165","author":"Giraldez","year":"2013","journal-title":"Am Heart J"},{"issue":"9324","key":"10.1016\/j.eprac.2026.01.006_bib159","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/S0140-6736(02)09089-X","article-title":"Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study","volume":"359","author":"Norhammar","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2213-8587(19)30388-2","article-title":"Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib161","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000787","article-title":"Adverse differences in cardiometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht Study","volume":"7","author":"de Ritter","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib162","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12872-020-01390-8","article-title":"Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study","volume":"20","author":"Hashemi Madani","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib163","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: from basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib164","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12872-017-0591-5","article-title":"Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study","volume":"17","author":"Halcox","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-020-01015-6","article-title":"Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study","volume":"19","author":"Jin","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib166","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jamainternmed.2019.0392","article-title":"Association of nonfasting vs fasting lipid levels with risk of major coronary events in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm","volume":"179","author":"Mora","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib167","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib168","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"25 Pt B","key":"10.1016\/j.eprac.2026.01.006_bib169","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9841","key":"10.1016\/j.eprac.2026.01.006_bib170","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib171","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1016\/j.eprac.2026.01.006_bib172","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"9716","key":"10.1016\/j.eprac.2026.01.006_bib173","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib174","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib175","article-title":"Correction to: statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"19","key":"10.1016\/j.eprac.2026.01.006_bib176","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009835","article-title":"Effects of coenzyme q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Qu","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib177","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamacardio.2022.4250","article-title":"Statin-associated muscle symptoms among new statin users randomly assigned to vitamin D or placebo","volume":"8","author":"Hlatky","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.eprac.2026.01.006_bib178","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib179","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4158\/EP171764.GL","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"25","key":"10.1016\/j.eprac.2026.01.006_bib180","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.eprac.2026.01.006_bib181","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/eurjpc\/zwad178","article-title":"An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology\/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study","volume":"30","author":"Singeisen","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.eprac.2026.01.006_bib182","series-title":"Repatha (evolocumab) injection, for subcutaneous use","year":"2025"},{"key":"10.1016\/j.eprac.2026.01.006_bib183","series-title":"Praluent (alirocumab) injection, for subcutaneous use","year":"2021"},{"issue":"21","key":"10.1016\/j.eprac.2026.01.006_bib184","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.eprac.2026.01.006_bib185","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.01.006_bib186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib187","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib188","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib189","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/eurjpc\/zwad331","article-title":"The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis","volume":"31","author":"Kim","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib191","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2026.01.006_bib192","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.eprac.2026.01.006_bib193","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.006_bib194","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1097\/HJH.0b013e32832d4aee","article-title":"Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004","volume":"27","author":"Suh","year":"2009","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib195","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/HYPERTENSIONAHA.118.11063","article-title":"Impacts of prediabetes mellitus alone or plus hypertension on the coronary severity and cardiovascular outcomes","volume":"71","author":"Liu","year":"2018","journal-title":"Hypertension"},{"issue":"7160","key":"10.1016\/j.eprac.2026.01.006_bib196","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"issue":"7258","key":"10.1016\/j.eprac.2026.01.006_bib197","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"issue":"10507","key":"10.1016\/j.eprac.2026.01.006_bib198","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(25)01391-1","article-title":"Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials","volume":"406","author":"Guo","year":"2025","journal-title":"Lancet"},{"issue":"10449","key":"10.1016\/j.eprac.2026.01.006_bib199","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.eprac.2026.01.006_bib200","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2025.07.055","article-title":"Effect of intensive blood pressure control on stroke: A prespecified secondary analysis of the ESPRIT trial","volume":"86","author":"Li","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.006_bib201","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an Endocrine Society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib202","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz293","article-title":"Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension","volume":"105","author":"Hu","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib203","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1507\/endocrj.EJ13-0060","article-title":"Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension","volume":"60","author":"Murase","year":"2013","journal-title":"Endocr J"},{"issue":"Suppl 2 Suppl 2","key":"10.1016\/j.eprac.2026.01.006_bib204","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.2337\/dcS13-2039","article-title":"Ambulatory blood pressure monitoring in the diagnosis and management of hypertension","volume":"36","author":"Grossman","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MBP.0b013e3283360ed1","article-title":"Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review","volume":"15","author":"Pierdomenico","year":"2010","journal-title":"Blood Press Monit"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib206","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.amjhyper.2006.12.013","article-title":"Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension","volume":"20","author":"Stergiou","year":"2007","journal-title":"Am J Hypertens"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib207","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/jhh.2010.54","article-title":"European Society of Hypertension practice guidelines for home blood pressure monitoring","volume":"24","author":"Parati","year":"2010","journal-title":"J Hum Hypertens"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib208","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib209","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.004473","article-title":"Exercise training for blood pressure: a systematic review and meta-analysis","volume":"2","author":"Cornelissen","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00045415-199909000-00013","article-title":"The dietary approaches to stop hypertension (DASH) clinical trial: implications for lifestyle modifications in the treatment of hypertensive patients","volume":"7","author":"Conlin","year":"1999","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.eprac.2026.01.006_bib211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjcard.2022.10.019","article-title":"Effects of diet on 10-year atherosclerotic cardiovascular disease risk (from the DASH Trial)","volume":"187","author":"Jeong","year":"2023","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib212","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3945\/ajcn.116.146803","article-title":"A Mediterranean diet lowers blood pressure and improves endothelial function: results from the MedLey randomized intervention trial","volume":"105","author":"Davis","year":"2017","journal-title":"Am J Clin Nutr"},{"issue":"25","key":"10.1016\/j.eprac.2026.01.006_bib213","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib214","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1681\/ASN.2018040443","article-title":"The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): a randomized, controlled trial","volume":"29","author":"Saglimbene","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.eprac.2026.01.006_bib215","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"9982","key":"10.1016\/j.eprac.2026.01.006_bib216","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.eprac.2026.01.006_bib217","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.eprac.2026.01.006_bib218","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib219","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"issue":"10008","key":"10.1016\/j.eprac.2026.01.006_bib220","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"1 Suppl 1","key":"10.1016\/j.eprac.2026.01.006_bib221","first-page":"S239","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.01.006_bib222","series-title":"Aldactone (spironolactone) tablets for oral use","year":"2018"},{"issue":"23","key":"10.1016\/j.eprac.2026.01.006_bib223","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib224","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.eprac.2026.01.006_bib225","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/eurheartj\/ehab886","article-title":"Corrigendum to: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.eprac.2026.01.006_bib226","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib228","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1467-789X.2001.00044.x","article-title":"Use of beta-blockers in obesity hypertension: potential role of weight gain","volume":"2","author":"Pischon","year":"2001","journal-title":"Obes Rev"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib229","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/01.HYP.37.2.250","article-title":"Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis","volume":"37","author":"Sharma","year":"2001","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib230","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib231","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib232","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2026.01.006_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105052","article-title":"Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists","volume":"160","author":"Berra","year":"2020","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib234","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00592-023-02154-4","article-title":"Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis","volume":"60","author":"Diallo","year":"2023","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13098-023-01092-z","article-title":"Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis","volume":"15","author":"Zhang","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib236","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib237","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/apt.13405","article-title":"Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE","volume":"43","author":"Doycheva","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib238","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib239","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","volume":"12","author":"Beghini","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"15","key":"10.1016\/j.eprac.2026.01.006_bib240","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.eprac.2026.01.006_bib241","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib242","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2026.01.006_bib243","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib244","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2026.01.006_bib245","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib246","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib247","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib248","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial","volume":"13","author":"Aggarwal","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib249","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib250","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib251","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib252","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.eprac.2026.01.006_bib253","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"9982","key":"10.1016\/j.eprac.2026.01.006_bib254","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib255","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib257","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jdiacomp.2015.04.007","article-title":"Prevalence of chronic kidney disease among individuals with diabetes in the SUPREME-DM project, 2005-2011","volume":"29","author":"Schroeder","year":"2015","journal-title":"J Diabetes Complications"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib262","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.eprac.2026.01.006_bib263","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2026.01.006_bib264","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib265","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib266","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib267","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib268","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/ndt\/gfaf064","article-title":"Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD","volume":"40","author":"Chuang","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"13","key":"10.1016\/j.eprac.2026.01.006_bib269","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3390\/diagnostics14131357","article-title":"Real-life experience on the effect of SGLT2 inhibitors vs. finerenone vs. combination on albuminuria in chronic kidney disease","volume":"14","author":"Hanouneh","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"25","key":"10.1016\/j.eprac.2026.01.006_bib270","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib271","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of liraglutide in type 2 diabetes and chronic kidney disease","volume":"15","author":"Mann","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib272","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.eprac.2026.01.006_bib273","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib274","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.eprac.2026.01.006_bib275","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib276","first-page":"846","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.eprac.2026.01.006_bib277","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"10193","key":"10.1016\/j.eprac.2026.01.006_bib278","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.eprac.2026.01.006_bib280","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.01.006_bib281","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.2337\/dcS15-3024","article-title":"Analyses of results from cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis","volume":"39","author":"Mannucci","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib282","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1755-5922.12075","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants","volume":"32","author":"Wu","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.eprac.2026.01.006_bib283","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.2147\/IJGM.S327075","article-title":"Stroke risk factors in United States: an analysis of the 2013-2018 National Health and Nutrition Examination Survey","volume":"14","author":"Ren","year":"2021","journal-title":"Int J Gen Med"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.006_bib284","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eprac.2026.01.006_bib285","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjcard.2021.05.043","article-title":"Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus","volume":"154","author":"Grewal","year":"2021","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib286","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00415-020-09813-4","article-title":"GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis","volume":"267","author":"Malhotra","year":"2020","journal-title":"J Neurol"},{"issue":"20","key":"10.1016\/j.eprac.2026.01.006_bib287","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.116.024863","article-title":"Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus","volume":"135","author":"Young","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib288","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","article-title":"Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis","volume":"48","author":"Lee","year":"2017","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib289","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamaneurol.2019.0079","article-title":"Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial","volume":"76","author":"Spence","year":"2019","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib290","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.117.030458","article-title":"Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke)","volume":"137","author":"Yaghi","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib291","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/dom.14687","article-title":"Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance","volume":"24","author":"Spence","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib292","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis","volume":"52","author":"Zhou","year":"2021","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib293","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94945-4","article-title":"Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Tsai","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib294","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib295","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib296","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib297","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary","volume":"67","year":"2024","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib298","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes Facts"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib299","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib300","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib301","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.01.006_bib302","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/flgastro-2024-102856","article-title":"Role of anti-diabetic medications in the management of MASLD","volume":"16","author":"Isaacs","year":"2025","journal-title":"Frontline Gastroenterology"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.006_bib303","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib304","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.3390\/ijms26125883","article-title":"Liraglutide reduces liver steatosis and improves metabolic indices in obese patients without diabetes: a 3-month prospective study","volume":"26","author":"Bo\u0142dys","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib305","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib306","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2026.01.006_bib307","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1182037","article-title":"New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Kongmalai","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib308","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/17474124.2023.2172397","volume":"17","author":"Gu","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.eprac.2026.01.006_bib309","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1007\/s00125-025-06527-y","article-title":"Time to approve glucagon-like peptide-1 receptor agonists for MASLD: a rational step based on robust evidence","volume":"68","author":"Arredouani","year":"2025","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib311","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib312","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib313","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eprac.2026.01.006_bib314","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2026.01.006_bib315","article-title":"Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib316","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.eprac.2026.01.006_bib317","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib318","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib319","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib320","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","article-title":"First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib321","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib322","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12072-024-10758-3","article-title":"Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"19","author":"Weng","year":"2025","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.eprac.2026.01.006_bib323","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib324","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: a prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib325","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib326","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1210\/clinem\/dgad249","article-title":"Canagliflozin and metabolic associated fatty liver disease in patients with diabetes mellitus: new insights from CANVAS","volume":"108","author":"Borisov","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib327","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/dom.14923","article-title":"Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin","volume":"25","author":"Corbin","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.01.006_bib328","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.eprac.2026.01.006_bib329","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s11606-020-06561-z","article-title":"Identifying risk factors for diabetic ketoacidosis associated with SGLT2 inhibitors: a nationwide cohort study in the USA","volume":"36","author":"Fralick","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib330","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/00325481.2016.1169894","article-title":"Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks","volume":"128","author":"Blonde","year":"2016","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib331","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib332","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib333","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2337\/dc20-0978","article-title":"Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT","volume":"44","author":"Abdul-Ghani","year":"2021","journal-title":"Diabetes Care"},{"issue":"10208","key":"10.1016\/j.eprac.2026.01.006_bib334","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib335","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2213-8587(13)70006-8","article-title":"Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"1","author":"Kramer","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib336","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12020-021-02889-6","article-title":"Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials","volume":"74","author":"Mannucci","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib337","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/dom.13871","article-title":"Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"22","author":"Men","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib338","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc06-1357","article-title":"Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups","volume":"30","author":"Yki-J\u00e4rvinen","year":"2007","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib339","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"issue":"10392","key":"10.1016\/j.eprac.2026.01.006_bib340","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(23)00520-2","article-title":"Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial","volume":"401","author":"Mathieu","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib341","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMoa2303208","article-title":"Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin","volume":"389","author":"Rosenstock","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib342","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2213-8587(23)00093-1","article-title":"Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial","volume":"11","author":"Philis-Tsimikas","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib343","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-8587(25)00096-8","article-title":"Once-weekly IcoSema versus once-weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open-label, multicentre, treat-to-target, randomised, phase 3a trial","volume":"13","author":"Mathieu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib344","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S2213-8587(25)00052-X","article-title":"Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial","volume":"13","author":"Billings","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.eprac.2026.01.006_bib345","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","article-title":"Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment","volume":"391","author":"Wysham","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib346","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2337\/cd19-0061","article-title":"Overbasalization: addressing hesitancy in treatment intensification beyond basal insulin","volume":"38","author":"Cowart","year":"2020","journal-title":"Clin Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib347","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2015-000171","article-title":"BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin","volume":"4","author":"Zisman","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib348","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1463-1326.2011.01459.x","article-title":"Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month \u2018proof-of-concept\u2019 study","volume":"13","author":"Owens","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib349","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1463-1326.2008.00967.x","article-title":"Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs","volume":"10","author":"Lankisch","year":"2008","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib350","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/dom.12528","article-title":"Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)","volume":"17","author":"Vora","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib351","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/emermed-2015-205637","article-title":"Dietary sugars versus glucose tablets for first-aid treatment of symptomatic hypoglycaemia in awake patients with diabetes: a systematic review and meta-analysis","volume":"34","author":"Carlson","year":"2017","journal-title":"Emerg Med J"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib352","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1932296814565131","article-title":"Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems","volume":"9","author":"Newswanger","year":"2015","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib353","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc17-1402","article-title":"Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog","volume":"41","author":"H\u00f6velmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib354","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002137","article-title":"Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies","volume":"9","author":"Christiansen","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib355","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc15-1498","article-title":"Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study","volume":"39","author":"Rickels","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib356","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1932296814557518","article-title":"Intranasal glucagon: a promising approach for treatment of severe hypoglycemia","volume":"9","author":"Pontiroli","year":"2015","journal-title":"J Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib357","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2337\/dc15-1606","article-title":"Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care"},{"issue":"Sup1","key":"10.1016\/j.eprac.2026.01.006_bib359","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00325481.2022.2147326","article-title":"Efficacy and safety of semaglutide for weight management: evidence from the STEP program","volume":"134","author":"Amaro","year":"2022","journal-title":"Postgrad Med"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib360","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib361","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"9741","key":"10.1016\/j.eprac.2026.01.006_bib362","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib363","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib364","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0011-393X(03)00126-7","article-title":"Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective study","volume":"64","author":"Li","year":"2003","journal-title":"Curr Ther Res Clin Exp"},{"issue":"7","key":"10.1016\/j.eprac.2026.01.006_bib365","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"issue":"10148","key":"10.1016\/j.eprac.2026.01.006_bib366","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eprac.2026.01.006_bib367","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","article-title":"Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Padwal","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"4","key":"10.1016\/j.eprac.2026.01.006_bib368","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib369","first-page":"155","article-title":"Double-blind, parallel-group, placebo-controlled multi-center clinical trial for evaluating the efficacy and safety of phentermine hydrochloride in obese patients","volume":"14","author":"Chang Jin","year":"2005","journal-title":"Korean J Obes"},{"issue":"6","key":"10.1016\/j.eprac.2026.01.006_bib370","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.pcd.2016.05.005","article-title":"Bias in the measure of the effectiveness of seasonal influenza vaccination among diabetics","volume":"10","author":"Casanova","year":"2016","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib371","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.23.1.95","article-title":"Use of influenza and pneumococcal vaccines in people with diabetes","volume":"23","author":"Smith","year":"2000","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib372","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2337\/dc20-2260","article-title":"COVID-19 severity is tripled in the diabetes community: A -prospective analysis of the -pandemic's impact in type 1 and type 2 diabetes","volume":"44","author":"Gregory","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2026.01.006_bib373","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1080\/21645515.2018.1446719","article-title":"Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: a systematic review","volume":"14","author":"Dos Santos","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib374","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","article-title":"Surveillance of vaccination coverage among adult populations -United States, 2018","volume":"70","author":"Lu","year":"2021","journal-title":"MMWR Surveill Summ"},{"issue":"3","key":"10.1016\/j.eprac.2026.01.006_bib375","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M13-2332","article-title":"U.S. physicians' perspective of adult vaccine delivery","volume":"160","author":"Hurley","year":"2014","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.01.006_bib376","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/003335491412900203","article-title":"Recommendations from the National Vaccine Advisory Committee: standards for adult immunization practice","volume":"129","year":"2014","journal-title":"Public Health Rep"},{"issue":"1","key":"10.1016\/j.eprac.2026.01.006_bib378","article-title":"Patient reminder and recall interventions to improve immunization rates","volume":"1","author":"Jacobson Vann","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7 Suppl 2","key":"10.1016\/j.eprac.2026.01.006_bib379","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjmed.2008.05.005","article-title":"Barriers to adult immunization","volume":"121","author":"Johnson","year":"2008","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.eprac.2026.01.006_bib380","first-page":"651","article-title":"Using the 4 pillars to increase vaccination among high-risk adults: who benefits?","volume":"23","author":"Nowalk","year":"2017","journal-title":"Am J Manag Care"}],"updated-by":[{"DOI":"10.1016\/j.eprac.2026.05.025","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000}},{"DOI":"10.1016\/j.eprac.2026.05.025","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26000224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T19:42:02Z","timestamp":1785094922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":370,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1530891X26000224"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.006","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes \u2013 2026 Update","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}